April 17th 2024
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer
February 16th 2024Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.
Treatment Considerations and AE Management Strategies with HER2-Directed Therapies
February 16th 2024Heather Moore, CPP, PharmD, presents a comprehensive summary of targeted therapies for HER2-positive breast cancer and provides expert insights into the management of adverse effects associated with these treatments.
TAC01-HER2 Cell Therapy Demonstrates Promising Clinical Activity in HER2+ Solid Tumors
November 14th 2022Interim data from the phase 1/2 TACTIC-2 trial indicated that treatment with TAC01-HER2 cell therapy produced a 67% disease control rate among a cohort of patients with HER2-positive solid tumors.